Shenzhen YHLO Biotech Management
Management criteria checks 3/4
Shenzhen YHLO Biotech's CEO is Yongbo Song, appointed in Dec 2012, has a tenure of 12.17 years. directly owns 0.21% of the company’s shares, worth CN¥19.11M. The average tenure of the management team and the board of directors is 8.3 years and 12.2 years respectively.
Key information
Yongbo Song
Chief executive officer
CN¥949.8k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 12.2yrs |
| CEO ownership | 0.2% |
| Management average tenure | 8.3yrs |
| Board average tenure | 12.2yrs |
Recent management updates
Recent updates
CEO
Yongbo Song (40 yo)
12.2yrs
Tenure
CN¥949,844
Compensation
Mr. Yongbo Song serves as Vice Chairman of the Board at Shenzhen YHLO Biotech Co., Ltd., since March 2019 and serves as General Manager and Director since December 2012.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Vice Chairman of the Board | 12.2yrs | CN¥949.84k | 0.21% CN¥ 19.1m | |
| CFO & Director | 2.2yrs | CN¥827.95k | 0.015% CN¥ 1.3m | |
| Deputy General Manager | 8.3yrs | CN¥1.62m | 0.43% CN¥ 38.7m |
8.3yrs
Average Tenure
45yo
Average Age
Experienced Management: 688575's management team is seasoned and experienced (8.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Vice Chairman of the Board | 12.2yrs | CN¥949.84k | 0.21% CN¥ 19.1m | |
| CFO & Director | 2.2yrs | CN¥827.95k | 0.015% CN¥ 1.3m | |
| Independent Director | 1.3yrs | CN¥22.50k | no data | |
| Chairman of the Board | 12.2yrs | CN¥565.23k | 47.1% CN¥ 4.2b | |
| Chairman of the Supervisory Board | 12.2yrs | no data | no data |
12.2yrs
Average Tenure
45yo
Average Age
Experienced Board: 688575's board of directors are seasoned and experienced ( 12.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/02 07:01 |
| End of Day Share Price | 2025/01/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shenzhen YHLO Biotech Co., Ltd. is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Shiyu Chen | China International Capital Corporation Limited |
| Wei Sun | China Merchants Securities Co. Ltd. |